Abstract 952P
Background
Transarterial chemoembolization (TACE) in combination with lenvatinib has been reported in several exploratory clinical studies in Chinese patients with hepatocellular carcinoma (HCC). Studies have showed good tumor response and survival benefit for combination therapy based on TACE plus lenvatinib in patients with advanced HCC. A multicenter, real-world study was conducted to explore the efficacy and safety of TACE in combination with lenvatinib as initial treatment for unresectable HCC patients in a real-world setting (PROLONG study, NCT04560751).
Methods
This real-world study was conducted at 7 centers in China. Eligible patients were aged more than 18 years old, with HCC, CNLC stage IIb-IIIb with unresectable diseases, Child-Pugh ≤7, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, no prior systemic therapy. All patients received TACE combined with lenvatinib, with or without immune checkpoint inhibitors. The primary endpoint was objective response rate (ORR), which was evaluated according to mRECIST, and secondary endpoints included organ-specific objective response rate, progression-free survival (PFS), AFP response rate and time to progression (TTP).
Results
A total of 197 patients were enrolled from August 2020 to February 2023, with 145 patients evaluable for efficacy. The ORR was 48.3% evaluated according to mRECIST, with a complete response (CR) rate of 8.3%, partial response (PR) rate of 40%. The disease control rate (DCR) was 86.2%. The median PFS was 10.2 months (95%CI, 5.9-14.5), and the median OS has not been reached. The most common adverse events (AE) were fever, elevated transaminases, and decreased platelets. No treatment-related grade 5 AE occurred.
Conclusions
Combination therapy based on TACE plus lenvatinib in patients with unresectable hepatocellular carcinoma showed promising efficacy in the real-world setting. No unexpected adverse events were observed.
Clinical trial identification
NCT04560751.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18